2019_4q_omron_e
31/39 HCB: Developing a Data Business

【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。



【ノート】
In addition to the wearable BPM we have just described, we have also been able to secure FDA approval for a BPM that is enabled for EKG readings as well, which was jointly developed with AliveCor. We have started selling the product in the North America this year. This device is able to simultaneously measure blood pressure and EKG, a world’s first. Going forward, we aim to use IT technologies to manage multiple vital sign data on an integrated basis, to capture early warning signs of acute medical events for use by doctors in making treatment decisions. By expanding beyond blood pressure data to EKG data, we see our business evolving into a personalized and preventative medicine business. Through this, we aim to support the development of individualized treatment. OMRON has continued to invest in developing revolutionary new devices, building out our sales network, and educational activities. We will continue our efforts to further build on our strengths. This is because these investments support further growth. We are committed to achieving strong growth in our HCB business going forward. We hope you will hold high expectations for OMRON.